Adam Craig Sells 47,436 Shares of X4 Pharmaceuticals (NASDAQ:XFOR) Stock

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Chairman Adam Craig sold 47,436 shares of the firm’s stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $4.44, for a total value of $210,615.84. Following the completion of the sale, the chairman directly owned 328,651 shares in the company, valued at approximately $1,459,210.44. The trade was a 12.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

X4 Pharmaceuticals Stock Performance

XFOR remained flat at $4.29 during midday trading on Thursday. The company’s stock had a trading volume of 964,359 shares, compared to its average volume of 562,019. X4 Pharmaceuticals, Inc. has a 52 week low of $2.45 and a 52 week high of $4.83. The firm has a 50-day simple moving average of $4.04 and a 200-day simple moving average of $3.96. The company has a current ratio of 10.18, a quick ratio of 9.98 and a debt-to-equity ratio of 0.45. The firm has a market capitalization of $425.35 million, a price-to-earnings ratio of -3.57 and a beta of 0.37.

X4 Pharmaceuticals (NASDAQ:XFOR) last announced its quarterly earnings data on Friday, August 7th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.05. X4 Pharmaceuticals had a negative net margin of 568.80% and a negative return on equity of 64.95%. The business had revenue of $8.81 million for the quarter, compared to analyst estimates of $2.42 million. On average, equities analysts expect that X4 Pharmaceuticals, Inc. will post -0.71 EPS for the current year.

Hedge Funds Weigh In On X4 Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Indivisible Partners purchased a new stake in shares of X4 Pharmaceuticals during the 4th quarter worth about $40,000. Rhumbline Advisers raised its holdings in X4 Pharmaceuticals by 5.4% in the first quarter. Rhumbline Advisers now owns 188,415 shares of the company’s stock valued at $44,000 after buying an additional 9,690 shares during the period. SummitTX Capital L.P. purchased a new position in X4 Pharmaceuticals in the first quarter valued at approximately $46,000. Pettinga Financial Advisors LLC acquired a new position in X4 Pharmaceuticals during the second quarter valued at approximately $47,000. Finally, Two Sigma Investments LP acquired a new position in X4 Pharmaceuticals during the third quarter valued at approximately $47,000. 72.03% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on XFOR shares. Leerink Partners began coverage on shares of X4 Pharmaceuticals in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $12.00 price target on the stock. Weiss Ratings cut shares of X4 Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday. Finally, Wells Fargo & Company began coverage on X4 Pharmaceuticals in a report on Friday, July 10th. They set an “overweight” rating and a $11.00 price objective for the company. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $11.25.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.